India, July 8 -- Earlier this year, Immuneel Therapeutics achieved a significant milestone by becoming one of the first Indian companies to receive regulatory approval for the commercial sale of a CAR-T therapy. However, as patient demand surged, Immuneel faced the challenge of scaling its all-in-one manufacturing platform-known for its clinical reliability but limited in cost-effective expansion. Recognising this bottleneck, ScaleReady stepped in with its G-Rex(R) Grant, selecting Immuneel as a strategic partner in India.

Josh Ludwig, Global Director of Commercial Operations at ScaleReady, speaks with BioSpectrum India about how this collaboration marks a turning point in industrial-scale cell and gene therapy (CGT) manufacturing in eme...